Core Viewpoint - The A-share market shows positive momentum with the Shanghai Composite Index closing at 4122.58 points, above the annual line, reflecting a slight increase of 0.14% [1] Group 1: Market Performance - The total trading volume of A-shares reached 27,165.07 billion yuan [1] - 120 A-shares have surpassed the annual line, indicating a bullish trend in the market [1] Group 2: Notable Stocks - Stocks with significant deviation rates include: - Teruisi (特瑞斯) with a deviation rate of 22.45% and a daily increase of 29.98% [1] - Qingyun Technology (青云科技) with a deviation rate of 17.76% and a daily increase of 20.00% [1] - Zhongbei Communication (中贝通信) with a deviation rate of 9.06% and a daily increase of 10.00% [1] - Other stocks with smaller deviation rates that have just crossed the annual line include: - Meiansen (梅安森) and Founder Securities (方正证券) [1]

证券代码：300326 证券简称：ST 凯利 公告编号：2026-005 上海凯利泰医疗科技股份有限公司 关于公司股票被实施其他风险警示相关事项的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 一、被实施其他风险警示暨可能被实施退市风险警示的相关情况 上海凯利泰医疗科技股份有限公司（以下简称"公司"）2024年度财务报告 内部控制被众华会计师事务所（特殊普通合伙）（以下简称"众华"）出具了无 法表示意见的审计报告。根据《深圳证券交易所创业板股票上市规则》（以下简 称"《创业板股票上市规则》"）第9.4条第（四）项规定，公司出现"（四） 最近一个会计年度财务报告内部控制被出具无法表示意见或者否定意见的审计 报告，或者未按照规定披露财务报告内部控制审计报告"的情形，公司股票交易 被深圳证券交易所实施其他风险警示；根据《深圳证券交易所创业板股票上市规 则》第 10.4.4 条第（五）项规定，上市公司出现"首个会计年度财务报告内部 控制被出具无法表示意见或者否定意见的审计报告，或者未按照规定披露财务报 告内部控制审计报告"的情形，上市公司应当立即披露股票交易可能 ...

上海凯利泰医疗科技股份有限公司 关于出售洁诺医疗管理集团有限公司股权并减资退出 上海景正医疗科技有限公司的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、交易概述 证券代码：300326 证券简称：ST 凯利 公告编号：2026-004 二○二六年一月十四日 2 为进一步聚焦业务发展，优化资源配置，推动战略转型，上海凯利泰医疗科 技股份有限公司（以下简称"公司"）于 2025 年 8 月 4 日召开第六届董事会第 九次会议，审议通过了《关于出售洁诺医疗管理集团有限公司股权并减资退出上 海景正医疗科技有限公司的议案》，同意公司通过上海景正医疗科技有限公司（以 下简称"景正医疗"）间接持有的洁诺医疗管理集团有限公司（以下简称"洁诺 医疗"）36.9000%的股权以 16,200 万元的交易价格出售给上海荟添医疗科技有 限公司（以下简称"荟添医疗"）。具体内容详见公司于 2025 年 8 月 5 日在巨潮 资讯网（www.cninfo.com.cn）披露的《上海凯利泰医疗科技股份有限公司关于 出售洁诺医疗管理集团有限公司股权并减资退出上海景正医疗科技有 ...

股份质押的公告 证券代码：300326 证券简称：ST 凯利 公告编号：2026-003 上海凯利泰医疗科技股份有限公司 关于持股 5%以上股东及其一致行动人 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 上海凯利泰医疗科技股份有限公司（以下简称"公司"）近日接到持股5% 以上股东上海欣诚意投资有限公司（以下简称"欣诚意"）及其一致行动人袁征 先生函告，获悉欣诚意、袁征对其所持有的本公司的股份办理了质押手续，现将 具体内容公告如下： | 一、股东股份质押的基本情况 股 东 名 称 是否为 控股股 东或第 | 本次 质押 | 占其所 | 占公 司总 | 是否为 | 是否为 | 质押起 | | 质押到 | 质权 | 质 押 用 途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 先生函告，获悉欣诚意、袁征对其所持有的本公司的股份办理了质押手续，现将 具体内容公告如下： | | | | 以上股东上海欣诚意投资有限公司（以下简称"欣诚意"）及其一致行动人袁征 | | | ...

证券代码：300326 证券简称：ST 凯利 公告编号：2026-001 上海凯利泰医疗科技股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、交易概述 为进一步聚焦业务发展，优化资源配置，巩固公司核心竞争能力，上海凯利 泰医疗科技股份有限公司（以下简称"公司"）于 2025 年 6 月 21 日召开第六届 董事会第八次会议，审议通过了《关于出售控股子公司股权的议案》，同意公司 将持有的江苏润志泰医疗科技有限公司（以下简称"润志泰"）51%的股权以 10,755,000.00 元交易价格出售给无锡优鸿泰企业管理有限公司（以下简称"优鸿 泰"）。具体内容详见公司于 2025 年 6 月 25 日在巨潮资讯网（www.cninfo.com.cn） 披露的《上海凯利泰医疗科技股份有限公司关于出售控股子公司股权的公告》（公 告编号：2025-057）。 二、交易进展情况 截至本公告披露日，公司已与协议各方签署《股权转让协议》，协议各方已 根据协议约定依法办理完成相关工商变更登记手续，公司已收到全部相关股权转 让款项，本次交易已完成交割，公司不再持有润志泰 ...

证券代码：300326 证券简称：ST 凯利 公告编号：2026-002 上海凯利泰医疗科技股份有限公司 关于聘任董事会秘书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 上海凯利泰医疗科技股份有限公司（以下简称"公司"或"凯利泰"）于 2025 年 10 月 21 日召开第六届董事会第十二次会议，会议审议通过了《关于聘任刘庆 女士为董事会秘书的议案》。根据《公司法》《深圳证券交易所创业板股票上市 规则》等法律法规、规范性文件及《公司章程》等有关规定，经董事会提名委员 会审核通过，公司董事会同意聘任刘庆女士为公司董事会秘书，聘任将在刘庆女 士取得董事会秘书资格证书后生效，至第六届董事会任期届满之日为止（简历详 见附件）。 目前刘庆女士已取得深圳证券交易所颁发的上市公司董事会秘书培训证明， 其熟悉履职相关的法律法规，具备所聘岗位的职责要求和相应履职能力，任职资 格符合《深圳证券交易所创业板股票上市规则》《公司章程》的有关规定，不存 在法律法规及其他规范性文件规定的不得担任公司高级管理人员及董事会秘书 的情形。 刘庆女士联系方式如下： 邮箱：KMC@shkmc ...

Group 1 - Haitai Xinguang, based in Qingdao, specializes in the research, production, and sales of medical endoscope instruments and optical products, being a leading enterprise in the domestic medical endoscope optical field [1][30] - The company has established long-term collaborations with international medical giants such as Karl Storz and Olympus, and its high-definition optical imaging technology supports navigation equipment for neurosurgery [1][30] - By 2026, the market demand for its high-end optical components is expected to further release due to the recovery of the medical device sector and the advancement of brain-computer interface medical applications [1][30] Group 2 - Huqiang Technology, registered in Yichang, focuses on special protective equipment, pharmaceutical packaging, and medical devices, with a strong advantage in public health emergency material supply [2][31] - Its medical protective equipment is applicable in sterile operating environments for brain-computer interface implantation surgeries, enhancing product competitiveness in the medical device sector [2][31] Group 3 - Zhengde Medical, headquartered in Shaoxing, is a leading enterprise in the medical dressing industry, with a product matrix covering medical dressings, infection control, and rehabilitation care [3][32] - The company's surgical infection control products meet the sterile operation requirements for brain-computer interface implantation surgeries, and its rehabilitation products cater to post-operative patient management needs [3][32] - By 2026, the surgical infection control consumables business is expected to see market growth as brain-computer interface medical applications accelerate [3][32] Group 4 - Linuo Pharmaceutical Packaging, based in Jinan, specializes in the research, production, and sales of pharmaceutical packaging materials, including sterile medical device packaging suitable for brain-computer interface components [4][33] - The company is gradually expanding into the high-end medical device packaging market, seizing opportunities in the brain-computer interface industry [4][33] Group 5 - Rendu Biotech, located in Shanghai, focuses on RNA molecular diagnostic technology, with applications in infection detection post-brain-computer interface implantation surgeries [5][34] - The company’s post-operative infection detection reagents are expected to see new demand growth by 2026 as brain-computer interface clinical surgeries are promoted [5][34] Group 6 - Huangshan Capsule, based in Anhui, specializes in the research and production of pharmaceutical hollow capsules, gradually expanding into medical device auxiliary materials [6][36] - The company’s medical capsule carriers can adapt to the encapsulation needs of sustained-release bioelectrodes in brain-computer interface devices [6][36] Group 7 - ST Kelly, headquartered in Suzhou, focuses on medical device research and production, particularly in ultrasound equipment and rehabilitation devices [7][37] - The company’s ultrasound diagnostic equipment can be used for pre-operative brain tissue imaging assessments in brain-computer interface surgeries [7][37] Group 8 - Aotai Biotech, based in Hangzhou, specializes in rapid diagnostic reagents, with its rapid infection detection reagents applicable in brain-computer interface clinical settings [8][38] - The company is developing rapid detection products for post-operative neurological function assessment related to brain-computer interfaces [8][38] Group 9 - Dongfang Ocean, located in Yantai, focuses on marine biological medical materials, with collagen materials applicable as coatings for brain-computer interface electrodes [9][39] - The company is increasing its R&D investment in the medical device sector, particularly in the integration of biological medical materials with brain-computer interface devices by 2026 [9][39] Group 10 - Shuoshi Biotech, based in Taizhou, specializes in nucleic acid detection technology, with products applicable for precise diagnosis of post-operative brain infections in brain-computer interface surgeries [10][40] - The company is exploring detection technologies related to neurotransmitters in brain-computer interfaces, aiming for breakthroughs in neurological disease diagnostics [10][40] Group 11 - Guofa Co., located in Beihai, focuses on pharmaceutical manufacturing and medical device sales, with a distribution network covering Guangxi and surrounding areas [11][41] - The company plans to increase its agency layout for high-end medical devices related to brain-computer interfaces by 2026 [11][41] Group 12 - Nanwei Co., based in Nantong, specializes in medical dressings and hygiene products, with its adhesive dressings suitable for post-operative care in brain-computer interface surgeries [12][42] - The company is enhancing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [12][42] Group 13 - Mingde Biotech, located in Wuhan, is a leading enterprise in the field of rapid diagnostic reagents, with products applicable for monitoring vital signs during brain-computer interface surgeries [13][43] - The company is developing rapid assessment devices for post-operative neurological function related to brain-computer interfaces [13][43] Group 14 - Hualan Co., based in Wuxi, specializes in medical rubber products, with its rubber sealing components applicable in fluid control systems for brain-computer interface devices [14][44] - The company is collaborating with research institutions to develop rubber insulation components for brain-computer interface electrodes [14][44] Group 15 - Yuyue Medical, headquartered in Danyang, is a leading enterprise in home medical devices, with products applicable in brain-computer interface surgeries [15][45] - The company is increasing its R&D on medical-grade rehabilitation robots, aiming to integrate brain-computer interface technology with rehabilitation devices [15][45] Group 16 - Shengxiang Biotech, located in Changsha, focuses on nucleic acid detection technology, with products applicable for rapid diagnosis of central nervous system infections post-brain-computer interface surgeries [16][46] - The company is exploring gene detection technologies related to neurological genetic diseases, expanding the application boundaries of molecular diagnostics [16][46] Group 17 - Jiga Development, based in Jinan, focuses on high-end medical device incubation and industrialization, particularly in brain-computer interface-related medical device enterprises [17][47] - The company is responsible for industrial park construction and resource integration for brain-computer interface medical device companies [17][47] Group 18 - Anxu Biotech, located in Hangzhou, specializes in rapid diagnostic reagents, with products applicable for instant infection screening during brain-computer interface surgeries [18][48] - The company is developing rapid detection products for neurotransmitters related to brain-computer interfaces, aiming for breakthroughs in neurological function assessment [18][48] Group 19 - Wantai Biotech, based in Beijing, is a comprehensive enterprise in biopharmaceuticals and medical devices, with products applicable for biochemical index detection post-brain-computer interface surgeries [19][49] - The company is exploring biopharmaceutical development related to brain-computer interfaces, seeking new growth points in nerve repair [19][49] Group 20 - Jiuan Medical, located in Tianjin, focuses on home health devices, with products applicable for synchronized monitoring of brain signals and vital signs in brain-computer interface scenarios [20][50] - The company is increasing its R&D investment in brain-computer interface wearable devices, aiming to create an intelligent medical ecosystem [20][50] Group 21 - Jidan Biotech, based in Nanjing, specializes in POCT reagents and instruments, with products applicable for cardiovascular function assessment in brain-computer interface surgeries [21][51] - The company is developing rapid detection products for post-operative cerebrovascular diseases related to brain-computer interfaces [21][51] Group 22 - Wanfeng Biotech, located in Guangzhou, is a leading enterprise in the POCT field, with products applicable for instant infection screening during brain-computer interface surgeries [22][52] - The company is developing neurobiomarker detection reagents to assess post-operative neurological function recovery, providing comprehensive support for brain-computer interface surgeries [22][52] Group 23 - Haier Biotech, based in Qingdao, specializes in low-temperature storage devices for biological materials, with applications in brain-computer interface-related biological sample preservation [23][53] - The company is increasing its R&D on high-end medical storage devices tailored for brain-computer interface biological materials by 2026 [23][53] Group 24 - Haooubo, located in Suzhou, focuses on immune diagnostic reagents and instruments, with products applicable for immune function assessment in brain-computer interface surgeries [24][54] - The company is developing detection reagents for immune rejection post-brain-computer interface implantation, providing technical support for surgical complications [24][54] Group 25 - Shandong Pharmaceutical Glass, based in Zibo, is a leading enterprise in pharmaceutical glass, with products applicable for insulation packaging of brain-computer interface electrodes [25][55] - The company is expanding into the high-end medical device glass materials market, targeting the brain-computer interface industry [25][55] Group 26 - Innotech, located in Langfang, specializes in infectious disease diagnostic reagents, with products applicable for pre-operative lung infection screening in brain-computer interface surgeries [26][56] - The company is developing rapid detection products for post-operative lung infections related to brain-computer interfaces, aiming for breakthroughs in post-operative complication detection [26][56] Group 27 - Jianer Kang, based in Changzhou, focuses on medical dressings and rehabilitation care products, with its antibacterial medical dressings applicable for post-operative care in brain-computer interface surgeries [27][59] - The company is increasing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [27][59]

证券代码：300326 证券简称：ST 凯利 公告编号：2025-117 上海凯利泰医疗科技股份有限公司 关于持股 5%以上股东股份解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 上海凯利泰医疗科技股份有限公司（以下简称"公司"）近日接到持股5% 以上股东上海欣诚意投资有限公司（以下简称"欣诚意"）函告，获悉欣诚意对 其所持有的本公司的股份办理了解除质押手续，现将具体内容公告如下： | 股东 | 是否为控股股东 或第一大股东及 | | 本次解除质 | 占其所持 | 占公司总 | 质押起始 | 质押解除 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 其一致行动人 | | 押数量（股） | 股份比例 | 股本比例 | 日 | 日 | 质权人 | | 欣诚意 | | 否 | 36,000,000 | 97.28% | 5.02% | 2025 年 6 月 日 19 | 2025 年 月 12 23 | 上海星富 德企业管 理合伙企 | | | | | | | | ...

证券代码：300326 证券简称：ST 凯利 公告编号：2025-116 上海凯利泰医疗科技股份有限公司（以下简称"公司"）2024年度财务报告 内部控制被众华会计师事务所（特殊普通合伙）（以下简称"众华"）出具了无 法表示意见的审计报告。根据《深圳证券交易所创业板股票上市规则》（以下简 称"《创业板股票上市规则》"）第9.4条第（四）项规定，公司出现"（四） 最近一个会计年度财务报告内部控制被出具无法表示意见或者否定意见的审计 报告，或者未按照规定披露财务报告内部控制审计报告"的情形，公司股票交易 被深圳证券交易所实施其他风险警示；根据《深圳证券交易所创业板股票上市规 则》第 10.4.4 条第（五）项规定，上市公司出现"首个会计年度财务报告内部 控制被出具无法表示意见或者否定意见的审计报告，或者未按照规定披露财务报 告内部控制审计报告"的情形，上市公司应当立即披露股票交易可能被实施退市 风险警示的风险提示公告。具体内容详见公司于2025年4月30日在巨潮资讯网披 露的《关于公司股票被实施其他风险警示暨停复牌的公告》（公告编号：2025-020）。 二、采取的措施及有关工作的进展情况 公司董事会对众华出具无 ...

证券代码：300326 证券简称：ST凯利 公告编号：2025-115 上海凯利泰医疗科技股份有限公司 关于上海证监局行政监管措施决定书相关问题的整改报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 上海凯利泰医疗科技股份有限公司（以下简称"公司"）于2025年10月 28日收到中国证券监督管理委员会上海监管局（以下简称"上海证监局"） 下发的《关于对上海凯利泰医疗科技股份有限公司采取责令整改措施并对袁 征、王正民、丁魁采取出具警示函措施的决定》（沪证监决〔2025〕199号） （以下简称"《决定书》"），并于当日在巨潮资讯网披露了《关于收到中 国证券监督管理委员会上海监管局行政监管措施决定书的公告》（公告编号： 2025-111）。 针对《决定书》提出的相关问题，公司董事会和管理层高度重视，立即向 公司全体董事、高级管理人员及相关部门人员进行了通报、传达，并召集相关 部门和人员对《决定书》所涉事项进行了全面梳理和深入分析。公司按照相关 法律法规和规范性文件的要求，结合公司实际情况，组织相关人员对《决定书 》中指出的问题进行了深刻反思和全面自查，并制定了切 ...